Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25051608 | 1.00 | KMT2A (0.34) | KMT2AUSP2KCNH2 | |
| SCHEMBL23508648 | 0.94 | KMT2A (0.33) | KMT2AKCNH2 | |
| SCHEMBL9965915 | 0.94 | KCNH2 (0.36) | KMT2AUSP2KCNH2 | |
| SCHEMBL23879675 | 0.93 | USP2 (0.33) | KMT2AUSP2 | |
| SCHEMBL15962734 | 0.93 | USP2 (0.33) | KMT2AUSP2 | |
| SCHEMBL15962899 | 0.91 | KMT2A (0.38) | KMT2AKCNH2 | |
| SCHEMBL23103572 | 0.87 | USP2 (0.33) | KMT2AUSP2 | |
| SCHEMBL13849462 | 0.87 | USP2 (0.33) | KMT2AUSP2 | |
| SCHEMBL23508666 | 0.86 | KMT2A (0.36) | KMT2AKCNH2 | |
| SCHEMBL15962882 | 0.85 | KCNH2 (0.39) | KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119277-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023077216-A1 | HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS FOR TREATING FUNGAL INFECTIONS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| EP-3763710-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Kala Pharmaceuticals, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9833453-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353123-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KMT2A 4824/4885USP2 3457/4885KCNH2 3015/4885 |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | KMT2A 1022/4885USP2 4334/4885KCNH2 2533/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KMT2A 4265/4885USP2 4207/4885KCNH2 409/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | KMT2A 4807/4885USP2 3551/4885KCNH2 3314/4885 |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | PCSK9, CFTR, SLC10A1 | KMT2A 4630/4885USP2 4584/4885KCNH2 3197/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | KMT2A 1237/4885USP2 4147/4885KCNH2 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.